Osteoporosis International

, Volume 30, Issue 3, pp 659–666 | Cite as

Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study

  • Dong Ryul LeeEmail author
  • Jungun Lee
Original Article



Using a nationwide database from the Korean National Health Insurance Service, this study showed that once-monthly oral ibandronate (150 mg) had better anti-fracture efficacy than once-monthly oral risedronate (150 mg), as seen on assessing overall and non-vertebral fractures among Korean elderly women with osteoporosis.


Once-monthly oral bisphosphonates have been used widely without appropriate comparison. Therefore, we aimed to compare the anti-fracture efficacy of once-monthly ibandronate (150 mg) and once-monthly risedronate (150 mg).


We conducted a retrospective cohort study among Korean women aged ≥ 60 years from 2006 to 2015 using a nationwide database from the National Health Insurance Service Senior Cohort. The primary outcome was the first occurrence of fracture related to osteoporosis after the initial prescription of bisphosphonates. A Cox proportional model was used to estimate the incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for overall and site-specific fractures between the two treatments, after adjusting for possible confounding factors.


After propensity score matching, the ibandronate and risedronate groups, with 3454 patients each, were assembled from 36,701 new once-monthly ibandronate or risedronate users. After 4 years of follow-up, the ibandronate group had significantly lower incidence rates of overall and non-vertebral fractures than the risedronate group (IRR 0.822, 95% CI 0.698–0.968, P = 0.919 and IRR 0.798, 95% CI 0.647–0.985, P = 0.036, respectively).


Once-monthly ibandronate (150 mg) shows better anti-fracture efficacy than once-monthly risedronate (150 mg). However, further large-scale studies are required to confirm our findings and to determine site-specific differences, especially regarding the vertebral and hip areas.


Bisphosphonate Fracture Ibandronate Osteoporosis Risedronate 


Funding information

This study was supported by Wonkwang University in 2017.

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Harvey N, Dennison E, Cooper C (2010) Osteoporosis: impact on health and economics. Nat Rev Rheumatol 6:99–105CrossRefGoogle Scholar
  2. 2.
    Johnell O (1997) The socioeconomic burden of fractures: today and in the 21st century. Am J Med 103:S20–S26CrossRefGoogle Scholar
  3. 3.
    Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022 – Industry Insights by Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Receptor Modulators, Rank Ligand Inhibitor, Calcitonin and Others. Accessed Apr 20 2018
  4. 4.
    Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861CrossRefGoogle Scholar
  5. 5.
    Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627CrossRefGoogle Scholar
  6. 6.
    Kastelan D, Lozo P, Stamenkovic D, Miskic B, Vlak T, Kolak Z, Milas Ahic J, Altabas V, Crncevic Orlic Z, Korsic M (2009) Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO study. Clin Rheumatol 28:321–326CrossRefGoogle Scholar
  7. 7.
    Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13CrossRefGoogle Scholar
  8. 8.
    Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, Wainberg MA (2002) Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 76:1753–1761CrossRefGoogle Scholar
  9. 9.
    Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis. Arthritis Rheum 44:1496–1503Google Scholar
  10. 10.
    Yoo JH, Moon SH, Ha YC, Lee DY, Gong HS, Park SY, Yang KH (2015) Osteoporotic fracture: 2015 position statement of the Korean Society for Bone and Mineral Research. J Bone Metab 22:175–181CrossRefGoogle Scholar
  11. 11.
    Szulc P, Bouxsein M (2011) Overview of Osteoporosis. Epidemiology and Clinical Management. International Osteoporosis Foundation Vertebral Fracture Initiative Resource Document Part I. Accessed 19 June 2018
  12. 12.
    Ko YJ, Kim JY, Lee J, Song HJ, Kim JY, Choi NK, Park BJ (2014) Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women. J Prev Med Public Health 47:36–46CrossRefGoogle Scholar
  13. 13.
    Faries DE, Leon AC, Maria HJ, Obenchain RL (2010) Analysis of observational health care data using SAS. SAS Institute Inc., CaryGoogle Scholar
  14. 14.
    Kleinbaum DG, Klein M (2012) Evaluating the proportional hazards assumption. In: Survival analysis: a self-learning text, 3rd edn. Springer, New York, pp 161–197Google Scholar
  15. 15.
    Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759CrossRefGoogle Scholar
  16. 16.
    Recker R, Stakkestad JA, Chesnut CH 3rd, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890–899CrossRefGoogle Scholar
  17. 17.
    Chesnut CH 3rd, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249CrossRefGoogle Scholar
  18. 18.
    Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H, Group MS (2013) Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int 93:137–146CrossRefGoogle Scholar
  19. 19.
    Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD (2009) Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 20:291–297CrossRefGoogle Scholar
  20. 20.
    Nakai K, Tobinai M, Hashimoto J, Iida S, Kawanishi T (2016) The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties. Eur J Drug Metab Pharmacokinet 41:139–147CrossRefGoogle Scholar
  21. 21.
    Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H (2003) A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the risedronate late phase II research group). Osteoporos Int 14:225–234CrossRefGoogle Scholar
  22. 22.
    Delmas PD, McClung MR, Zanchetta JR et al (2008) Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36–42CrossRefGoogle Scholar
  23. 23.
    Harris ST, Watts NB, Genant HK, McKeever C, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 282:1344–1352CrossRefGoogle Scholar
  24. 24.
    Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:83–91CrossRefGoogle Scholar
  25. 25.
    Lindsay R (2007) Beyond clinical trials: the importance of large databases in evaluating differences in the effectiveness of bisphosphonate therapy in postmenopausal osteoporosis. Bone 40:S32–S35CrossRefGoogle Scholar
  26. 26.
    Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinary patients. Osteoporos Int 11:533–536CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  1. 1.Department of Family Medicine, Wonkwang University School of MedicineWonkwang University Sanbon HospitalGunpo-siRepublic of Korea

Personalised recommendations